Industry Outlook
Devic's syndrome (Neuromyelitis optica) treatment accounted for a market value of US$ 217.7 Mn in 2021 and projected to grow at a CAGR of 12.0% during the forecast period from 2022 to 2030. Devic's disease or neuromyelitis optica is an autoimmune disease in which antibodies and immune system cells mainly damage the optic nerves and the spinal cord, but in a few cases affect the brain. The injury to optical nerves leads to inflammation and soreness leading to vision loss and pain; the injury to the spinal cord leads to paralysis in the arms or legs, loss of sensation, and problems with bladder & bowel function. The key factors responsible for growth of global Devic's syndrome treatment market are rising awareness & prevalence related to orphan diseases, the recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.
Soliris (Eculizumab) will aid the significant growth of Devic's Syndrome treatment market throughout the forecast period
Soliris (Eculizumab) is a terminal complement inhibitor owned by Alexion. Soliris works by specifically preventing activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic s syndrome. Patients suffering with Devic s syndrome possess AQP4 antibody-positive, the body s immune system can turn against itself to produce autoantibodies against AQP4. Activation of anti-AQP4 autoantibodies leads to damage of vital cells in the CNS assisting further demyelination and death of neurons, primarily in the optic nerve and spinal cord. There are three promising molecules in Devic s syndrome treatment pipeline such as Satralizumab - Phase 3 (Hoffmann-La Roche/ Chugai Pharmaceutical), MEDI-551- Phase 2/3 (MedImmune LLC), and RC18 - Phase 3 (RemeGen, Ltd.). Chugai Pharmaceutical launched Phase 2 results related to Satralizumab on 15 October 2020; it is an investigational humanized anti-IL-6 receptor recycling monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
North America dominated the overall global market specifically due to recent drug approval, promising drugs in pipeline, and developed diagnostic landscape
In 2021, North America dominated the market and anticipated to retain its position throughout the forecast period due to high awareness related to orphan diseases, rising requirement for target-specific molecules to treat Devic s Syndrome, and easy adaptability & accessibility for newly launched drug. According to National Multiple Sclerosis Society, there are around 4,000 people suffering with Devic's syndrome in the United States with majority of women population. Asia Pacific will grow during the forecast period from 2022 to 2030, due to increasing awareness related to Devic s Syndrome assisting the rise in diagnosis & treatment rate in patients suffering with rare diseases.
The major companies involved in the Devic's Syndrome treatment industry studied based on financial data, product portfolio, current press releases, and key market strategies. This report also covers attractive investment proposition analyzed based on exclusive geographical PESTEL analysis. Major companies included in the report are Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Mylan Pharmaceuticals, Inc., Chugai Pharmaceutical, MedImmune LLC, and RemeGen, Ltd. among others.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Devic's Syndrome Treatment market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Devic's Syndrome Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drugs
- Eculizumab
- Methylprednisolone
- Azathioprine
- Mycophenolate Mofetil
- Rituximab
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Devic's Syndrome Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Devic's Syndrome Treatment market?
- Which is the largest regional market for Devic's Syndrome Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Devic's Syndrome Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Devic's Syndrome Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Devic's Syndrome Treatment Market
2.2. Global Devic's Syndrome Treatment Market, By Drugs, 2021 (US$ Million)
2.3. Global Devic's Syndrome Treatment Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Devic's Syndrome Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Devic's Syndrome Treatment Market Vendors
3.2. Strategies Adopted by Devic's Syndrome Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Devic's Syndrome Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Devic's Syndrome Treatment Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Eculizumab
5.3.2. Methylprednisolone
5.3.3. Azathioprine
5.3.4. Mycophenolate Mofetil
5.3.5. Rituximab
6. North America Devic's Syndrome Treatment Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
6.3.Devic's Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7. UK and European Union Devic's Syndrome Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.Devic's Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8. Asia Pacific Devic's Syndrome Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.Devic's Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
9. Latin America Devic's Syndrome Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
9.3.Devic's Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
10. Middle East and Africa Devic's Syndrome Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
10.3.Devic's Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Devic's Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
11. Company Profile
11.1. Alexion Pharmaceuticals, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Teva Pharmaceuticals
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Fresenius Kabi AG
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Pharmacia & Upjohn (a subsidary of Pfizer)
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Lupin Ltd.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Sagent Pharmaceuticals, Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Zydus Pharmaceuticals, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Sandoz Inc. (a subsidiary of Novartis)
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Alkem Laboratories Ltd.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Mylan Pharmaceuticals, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Hoffmann-La Roche/ Chugai Pharmaceutical
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. MedImmune LLC
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. RemeGen, Ltd.
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
List of Figures
Figure 1 Global Devic's Syndrome Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Devic's Syndrome Treatment Market: Quality Assurance
Figure 5 Global Devic's Syndrome Treatment Market, By Drugs, 2021
Figure 6 Global Devic's Syndrome Treatment Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Devic's Syndrome Treatment Market, 2021
Figure 8 Market Positioning of Key Devic's Syndrome Treatment Market Players, 2021
Figure 9 Global Devic's Syndrome Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Devic's Syndrome Treatment Market, By Drugs, 2021 Vs 2030, %
Figure 11 U.S. Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 12 Canada Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 14 UK Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 15 Germany Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 16 Spain Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 17 Italy Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 18 France Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 20 China Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 21 Japan Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 22 India Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 23 Australia Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 24 South Korea Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 26 Brazil Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 27 Mexico Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 29 GCC Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 30 Africa Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Devic's Syndrome Treatment Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 2 North America Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 3 U.S. Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 4 Canada Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 5 Rest of North America Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 6 UK and European Union Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 7 UK Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 8 Germany Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 9 Spain Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 10 Italy Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 11 France Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 12 Rest of Europe Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 13 Asia Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 14 China Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 15 Japan Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 16 India Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 17 Australia Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 18 South Korea Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 19 Latin America Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 20 Brazil Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 21 Mexico Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 22 Rest of Latin America Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 23 Middle East and Africa Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 24 GCC Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 25 Africa Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Devic's Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Companies Mentioned
- Alexion Pharmaceuticals Inc.
- Teva Pharmaceuticals
- Fresenius Kabi AG
- Pharmacia & Upjohn (a subsidary of Pfizer)
- Mylan Pharmaceuticals Inc.
- Chugai Pharmaceutical
- MedImmune LLC
- and RemeGen Ltd.
